Mike Riley, CEO of Veranova, discusses how people-first leadership, deep experience in complex chemistries, and close collaboration with customers position the CDMO to support increasingly complex modalities.
Sponsored by Veranova
Mike Riley, CEO of Veranova, explains how his experience in the CDMO industry has shaped a leadership approach centered on people. He describes people as Veranova’s number one value, which extends beyond hiring top talent to developing that talent and setting high standards in a business that, at the end of the day, is about delivering medicines to patients.
Riley discusses how customer expectations are changing as drug pipelines move toward more complex modalities, and why experience and transparent, collaborative partnerships matter more as development challenges increase. He points to Veranova’s more than 20 years of experience in antibody-drug conjugate (ADC) linker-payloads, its expansion of highly potent API capacity at its Devens, Massachusetts, facility, and a patented peptide manufacturing technology the company is developing with partners to improve efficiency, cost of goods, reliability of supply, and environmental sustainability. He also addresses supply chain resilience, highlighting Veranova’s two FDA- and DEA-approved US facilities in Devens, Massachusetts, and West Deptford, New Jersey.
Pharmaceutical and biotech professionals evaluating CDMO outsourcing partners for complex small molecules, ADCs, peptides, oligonucleotides, or US-based manufacturing will gain insight into how a specialist CDMO is investing in capacity and people to meet demand. Riley closes by sharing his view of where Veranova sees potentially double-digit growth and what he believes will define the company’s success in bringing the next generation of medicines to patients.
